Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 46, Issue 2, Pages 550-555Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.46.2.550-555.2002
Keywords
-
Categories
Ask authors/readers for more resources
The in vitro activities of faropenem and other antimicrobial agents were determined against 4,725 Streptococcus pneumoniae isolates, 2,614 Haemophilus influenzae isolates, and 1,193 Moraxella catarrhalis isolates collected from 273 U.S. laboratories during 1999. Faropenem MICs at which 90% of isolates are inhibited were 0.008, 0.25, and 1 mug/ml for penicillin-susceptible, -intermediate, and -resistant S. pneumoniae strains. respectively; 0.5 and 1 mug/ml for beta-lactamase-positive and -negative H. influenzae strains, respectively; and 0.12 and 0.5 mug/ml for beta-lactamase-negative and -positive M. catarrhalis strains, respectively. Faropenem holds promise as an oral therapy for community-acquired respiratory tract infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available